Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05705076
Other study ID # R.22.10.1907.R1.R2.R3
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date January 24, 2023
Est. completion date June 25, 2024

Study information

Verified date January 2023
Source Mansoura University
Contact Nshaat Elsaadany
Phone 01011868166
Email nshaatelsaadany@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Direct Oral Anticoagulants INTRODUCTION: DOAC's looks like an attractive alternative to VKA because they offer important advantages beyond their easiness of administration, like less interactions and no need of laboratory monitoring. 1 All oral anticoagulant regimens but not aspirin were associated with a lower risk of recurrent VTE, while only VKAs were associated with a higher risk of major bleeding. 2 There have been significant differences between VKAs and DOACs in the risk of major bleeding by the current study size. Even though the risk of major bleeding with VKAs may be lower in patients already challenged to anticoagulation treatment. 3 Furthermore, when deciding on longer term secondary prevention of VTE, DOACs appeared safer than standard-intensity VKAs, taking clinically relevant bleeding or any bleeding into consideration.4-5 Until now there is no randomized controlled trial assessing the role of oral direct anticoagulant as a prophylaxis for catheter associated venous thromboembolism. Aim of the work: To evaluate the efficacy of direct oral anticoagulants as a prophylactic anticoagulation in thromboprophylaxis of catheter induced thrombosis. Patients and methods Study location: The study will be conducted at the department of vascular surgery in Mansoura University, Faculty of Medicine, Mansoura, Egypt . Type of study: Randomized Controlled Prospective study Study duration: 2 years: 2022-2024 Sample size: It will include all patients presented to our department fulfilling the inclusion criteria. Study population: The study will be conducted in patients with any permanent catheter inserted intravenous either femoral or jugular either for hemodialysis or replacement therapy . Inclusion criteria: Any permanent catheter inserted intravenous either femoral or jugular either for hemodialysis, replacement or chemotherapy. Exclusion criteria: History of central venous occlusion, contraindication of direct oral anticoagulants. Consent: Patients must sign informed consent about possible complications from the therapy. Data collection: The demographics, symptoms, and preoperative clinical data will be collected. History Data: including underlying medical conditions, any previous associated morbidity. Examination: Venous examinations. Laboratory: Blood picture, Blood sugar level, Kidney functions, Liver functions and Coagulation profile. Imaging: Duplex US Method of Randomization: Computer-based Therapies group A : Apixaban 2.5 mg twice group B : Rivaroxaban 10 mg plus placebo group C : Placebo without anticoagulation Follow up All patients are followed by duplex ultrasonography to assess the thrombosis at the tip of catheter or around the catheter 10 days postoperative and 1, 3, 6, months then after one year, venography is indicated if the clinical evaluation not matched with sonographic results.


Description:

INTRODUCTION: DOAC's looks like an attractive alternative to VKA because they offer important advantages beyond their easiness of administration, like less interactions and no need of laboratory monitoring. 1 All oral anticoagulant regimens but not aspirin were associated with a lower risk of recurrent VTE, while only VKAs were associated with a higher risk of major bleeding. 2 There have been significant differences between VKAs and DOACs in the risk of major bleeding by the current study size. Even though the risk of major bleeding with VKAs may be lower in patients already challenged to anticoagulation treatment. 3 Furthermore, when deciding on longer term secondary prevention of VTE, DOACs appeared safer than standard-intensity VKAs, taking clinically relevant bleeding or any bleeding into consideration.4-5 Until now there is no randomized controlled trial assessing the role of oral direct anticoagulant as a prophylaxis for catheter associated venous thromboembolism. Aim of the work: To evaluate the efficacy of direct oral anticoagulants as a prophylactic anticoagulation in thromboprophylaxis of catheter induced thrombosis. Patients and methods Study location: The study will be conducted at the department of vascular surgery in Mansoura University, Faculty of Medicine, Mansoura, Egypt . Type of study: Randomized Controlled Prospective study Study duration: 2 years: 2022-2024 Sample size: It will include all patients presented to our department fulfilling the inclusion criteria. Study population: The study will be conducted in patients with any permanent catheter inserted intravenous either femoral or jugular either for hemodialysis or replacement therapy . Inclusion criteria: Any permanent catheter inserted intravenous either femoral or jugular either for hemodialysis, replacement or chemotherapy. Exclusion criteria: History of central venous occlusion, contraindication of direct oral anticoagulants. Consent: Patients must sign informed consent about possible complications from the therapy. Data collection: The demographics, symptoms, and preoperative clinical data will be collected. History Data: including underlying medical conditions, any previous associated morbidity. Examination: Venous examinations. Laboratory: Blood picture, Blood sugar level, Kidney functions, Liver functions and Coagulation profile. Imaging: Duplex US Method of Randomization: Computer-based Therapies Group A : Apixaban 2.5 mg twice Group B : Rivaroxaban 10 mg plus placebo Group C : Placebo without anticoagulation Follow up All patients are followed by duplex ultrasonography to assess the thrombosis at the tip of catheter or around the catheter 10 days postoperative and 1, 3, 6, months then after one year, venography is indicated if the clinical evaluation not matched with sonographic results. Statistical analysis ยท The data will be analyzed using Statistical Package for the Social Sciences. The numerical outcomes e.g. age is calculated as mean. Gender will be recorded as frequency and percentage. Chi Square test is applied to assess the association of various parameters. The results will be considered statistically significant if the p-value is found to be less than or equal to 0.05.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 1100
Est. completion date June 25, 2024
Est. primary completion date March 25, 2024
Accepts healthy volunteers No
Gender All
Age group 10 Years to 95 Years
Eligibility Inclusion Criteria: - Any permanent catheter inserted intravenous either femoral or jugular either for hemodialysis, replacement or chemotherapy. Exclusion Criteria: - History of central venous occlusion, contraindication of direct oral anticoagulants.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
catheter induced thromboprophylaxis
Direct oral anticoagulation for catheter induced thromboprophylaxis

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Mansoura University

Outcome

Type Measure Description Time frame Safety issue
Primary thromboprophylaxis of catheter induced thrombosis Prevention of thrombosis 6 months
Secondary Duplex ultrasonography duplex ultrasonography of central venous system 6 months
See also
  Status Clinical Trial Phase
Completed NCT04719182 - Practice of Adjunctive Treatments in Intensive Care Unit Patients With COVID-19
Not yet recruiting NCT04849312 - Prediction of 30-Day Readmission Using Machine Learning
Active, not recruiting NCT04784351 - Prediction of Expected Length of Hospital Stay Using Machine Learning
Active, not recruiting NCT05045742 - Prediction of Patient Deterioration Using Machine Learning
Recruiting NCT03885180 - Randomized Evaluation of D-dimer Guiding dUration of Oral antiCoagulation thErapy N/A
Completed NCT03203759 - Hospital-Level Care at Home for Acutely Ill Adults N/A
Not yet recruiting NCT04891861 - Restart TICrH Alpha Pilot Protocol, Restarting DOACs After Traumatic Intracranial Hemorrhage Phase 3
Recruiting NCT03524222 - Home Hospital for Suddenly Ill Adults N/A
Completed NCT04531280 - Rural Home Hospital: Proof of Concept N/A
Recruiting NCT06341231 - Personalized Anticoagulant Therapy for Pulmonary Thromboembolism
Completed NCT03926780 - Comparative Study of Oral Anticoagulation in Left Ventricular Thrombi Phase 3
Completed NCT04080570 - Remote Physician Care for Home Hospital Patients N/A
Not yet recruiting NCT03217799 - Noninvasive Measurement of Blood Coagulation N/A